Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

300P - Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Breast Cancer

Presenters

Emma Zattarin

Citation

Annals of Oncology (2020) 31 (suppl_4): S348-S395. 10.1016/annonc/annonc268

Authors

E. Zattarin1, C. Fabbroni1, F. Ligorio1, A. Marra2, C. Corti2, O. Bernocchi3, M. Sirico4, D.G. Generali4, G. Curigliano2, G. Bianchi1, G. Capri1, L. Rivoltini5, F.G.M. De Braud1, C. Vernieri1

Author affiliations

  • 1 Dipartimento Di Oncologia Medica, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 2 Divisione Sviluppo Di Nuovi Farmaci Per Terapie Innovative, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 3 Department Of Medical, Surgery And Health Sciences, University of Trieste, 34127 - Trieste/IT
  • 4 Breast Cancer Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona/IT
  • 5 Unit Of Immunotherapy Of Human Tumors, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milano/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 300P

Background

Preclinical evidence indicates that Cyclin-Dependent Kinase 4/6 inhibitors (CDK 4/6i) stimulate antitumor immunity as part of their antineoplastic activity. The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) are easy-to-measure indicators of systemic inflammation and immune system functional status. We investigated their association with CDK 4/6i efficacy in patients (pts) with hormone receptor-positive HER2-negative advanced breast cancer (HR+ HER2- aBC).

Methods

We conducted a retrospective, observational, multicenter Italian study to investigate the association between NLR or PLR, as measured at baseline and after the first 3 treatment cycles, and progression free survival (PFS) in HR+ HER2- aBC pts treated with CDK 4/6i plus endocrine therapies (ETs). The thresholds for NLR and PLR were defined through the maximally selected rank statistics. The impact of these parameters on PFS was evaluated at univariate and multivariable analysis by using Cox proportional hazard model.

Results

308 pts were treated with palbociclib (n=256), ribociclib (n=39) or abemaciclib (n=13) plus ETs. Of them, 168 (54.5%) pts received CDK 4/6i as first-line, 88 (28.6%) as second-line, and 52 (16.9%) as third- or subsequent line of treatment for advanced disease between January 2017 and March 2020. With a median follow-up of 16.8 months (95% CI, 15.1-18.2), median PFS in the whole pt population was 17.1 months (95% CI, 14.6-25.0). At multivariable analysis, we found an independent association between high NLR or PLR and lower PFS, both when these parameters were evaluated at baseline (aHR 1.57, 95% CI 1.07-2.29, p=0.02 and aHR 1.97, 95% CI 1.29-3.02, p=0.002, respectively) and after the first 3 treatment cycles (aHR 2.73, 95% CI 1.37-5.46, p=0.005 and aHR 2.13, 95% CI 1.21-3.77, p=0.009, respectively).

Conclusions

This is the first study to show a significant association between high baseline or on-treatment NLR or PLR values and lower PFS in HR+ HER2- aBC pts. Although our results need prospective validation, they suggest that NLR and PLR could be used as precocious biomarkers of treatment efficacy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

D.G. Generali: Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer. G. Curigliano: Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Honoraria (institution), Advisory/Consultancy: Novartis; Honoraria (institution), Advisory/Consultancy: lilly; Honoraria (institution), Advisory/Consultancy: Roche; Advisory/Consultancy: Ellipses Pharma; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Celltrion. G. Bianchi: Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Novartis. F.G.M. De Braud: Advisory/Consultancy: Tiziana Life Sciences; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Research grant/Funding (institution): Celgene; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy: Servier; Advisory/Consultancy: Pharm Research Associated; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Ignyta; Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy: Octimet Oncology; Advisory/Consultancy, Research grant/Funding (institution): Incyte; Speaker Bureau/Expert testimony: Pierre Fabre; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Gentili; Advisory/Consultancy: Dephaforum; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Bayer; Advisory/Consultancy: Fondazione Menarini. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.